Resveratrol Affects Sphingolipid Metabolism in A549 Lung Adenocarcinoma Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
17 Sep 2022
Historique:
received: 26 08 2022
revised: 14 09 2022
accepted: 15 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 28 9 2022
Statut: epublish

Résumé

Resveratrol is a naturally occurring polyphenol which has various beneficial effects, such as anti-inflammatory, anti-tumor, anti-aging, antioxidant, and neuroprotective effects, among others. The anti-cancer activity of resveratrol has been related to alterations in sphingolipid metabolism. We analyzed the effect of resveratrol on the enzymes responsible for accumulation of the two sphingolipids with highest functional activity-apoptosis promoting ceramide (CER) and proliferation-stimulating sphingosine-1-phosphate (S1P)-in human lung adenocarcinoma A549 cells. Resveratrol treatment induced an increase in CER and sphingosine (SPH) and a decrease in sphingomyelin (SM) and S1P. Our results showed that the most common mode of CER accumulation, through sphingomyelinase-induced hydrolysis of SM, was not responsible for a CER increase despite the reduction in SM in A549 plasma membranes. However, both the activity and the expression of CER synthase 6 were upregulated in resveratrol-treated cells, implying that CER was accumulated as a result of stimulated de novo synthesis. Furthermore, the enzyme responsible for CER hydrolysis, alkaline ceramidase, was not altered, suggesting that it was not related to changes in the CER level. The enzyme maintaining the balance between apoptosis and proliferation, sphingosine kinase 1 (SK1), was downregulated, and its expression was reduced, resulting in a decrease in S1P levels in resveratrol-treated lung adenocarcinoma cells. In addition, incubation of resveratrol-treated A549 cells with the SK1 inhibitors DMS and fingolimod additionally downregulated SK1 without affecting its expression. The present studies provide information concerning the biochemical processes underlying the influence of resveratrol on sphingolipid metabolism in A549 lung cancer cells and reveal possibilities for combined use of polyphenols with specific anti-proliferative agents that could serve as the basis for the development of complex therapeutic strategies.

Identifiants

pubmed: 36142801
pii: ijms231810870
doi: 10.3390/ijms231810870
pmc: PMC9505893
pii:
doi:

Substances chimiques

Antioxidants 0
Ceramides 0
Lysophospholipids 0
Neuroprotective Agents 0
Polyphenols 0
Sphingolipids 0
Sphingomyelins 0
sphingosine 1-phosphate 26993-30-6
Sphingomyelin Phosphodiesterase EC 3.1.4.12
Alkaline Ceramidase EC 3.5.1.23
Fingolimod Hydrochloride G926EC510T
Sphingosine NGZ37HRE42
Resveratrol Q369O8926L

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Bulgarian Ministry of Education and Science
ID : Contract DО1-154/28/08/2018

Références

Trends Endocrinol Metab. 2009 Jan;20(1):34-42
pubmed: 19008117
J Agric Food Chem. 2000 Apr;48(4):1243-6
pubmed: 10775379
Int J Mol Med. 2021 Jan;47(1):374-386
pubmed: 33236138
Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50
pubmed: 18216770
Chem Biol Interact. 2019 Sep 1;310:108731
pubmed: 31265827
J Biol Chem. 2002 Jul 19;277(29):25847-50
pubmed: 12011103
Chem Biol Interact. 2014 Jan 25;207:74-80
pubmed: 24183824
Clin Chest Med. 2002 Mar;23(1):1-25
pubmed: 11901905
Future Oncol. 2010 Oct;6(10):1603-24
pubmed: 21062159
Nature. 2001 Jun 14;411(6839):843-7
pubmed: 11459067
Neuromolecular Med. 2010 Dec;12(4):351-61
pubmed: 20607622
Int J Mol Sci. 2019 Sep 02;20(17):
pubmed: 31480728
Nature. 1996 Jun 27;381(6585):800-3
pubmed: 8657285
J Clin Invest. 2016 Jan;126(1):254-65
pubmed: 26650179
Br J Cancer. 2016 Jun 28;115(1):115-21
pubmed: 27253177
Br J Pharmacol. 2012 Jul;166(5):1605-16
pubmed: 22251058
Cancer Lett. 2007 May 8;249(2):143-7
pubmed: 16996206
J Biol Chem. 2014 Aug 1;289(31):21663-72
pubmed: 24928506
J Biol Chem. 2011 May 27;286(21):18633-40
pubmed: 21464128
Arch Biochem Biophys. 2009 Jan 1;481(1):72-9
pubmed: 18952047
Cancer Lett. 2007 Aug 8;253(1):124-30
pubmed: 17321671
Annu Rev Biophys Biomol Struct. 2004;33:269-95
pubmed: 15139814
Curr Med Chem. 2008;15(19):1887-98
pubmed: 18691046
Nat Rev Cancer. 2013 Jan;13(1):51-65
pubmed: 23235911
Experientia. 1977 Feb 15;33(2):151-2
pubmed: 844529
Nat Rev Drug Discov. 2013 Sep;12(9):688-702
pubmed: 23954895
Cell Immunol. 2014 Jul;290(1):21-9
pubmed: 24859013
Curr Drug Targets. 2007 Jan;8(1):155-67
pubmed: 17266539
Free Radic Biol Med. 2019 Apr;134:527-544
pubmed: 30735839
Nat Rev Drug Discov. 2010 Nov;9(11):883-97
pubmed: 21031003
Nat Rev Drug Discov. 2006 Jun;5(6):493-506
pubmed: 16732220
Essays Biochem. 2020 Sep 23;64(3):579-589
pubmed: 32579188
FASEB J. 2009 Aug;23(8):2412-24
pubmed: 19346296
Biochem Pharmacol. 2007 Jul 15;74(2):281-9
pubmed: 17521618
Curr Drug Targets. 2008 Aug;9(8):662-73
pubmed: 18691013
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Jun;1865(6):158675
pubmed: 32112978
Int J Biochem Cell Biol. 2012 Sep;44(9):1457-64
pubmed: 22634604
EBioMedicine. 2021 Apr;66:103301
pubmed: 33813137
Biochim Biophys Acta. 2015 Nov;1851(11):1482-9
pubmed: 26253821
Anticancer Agents Med Chem. 2019;19(1):121-129
pubmed: 30585550
Int J Cancer. 2018 May 15;142(10):2153-2162
pubmed: 29277894
J Biochem Mol Biol. 2006 Mar 31;39(2):113-31
pubmed: 16584625
J Agric Food Chem. 2004 Jul 28;52(15):4713-9
pubmed: 15264904
Nutrition. 2017 Feb;34:108-117
pubmed: 28063505
FASEB J. 2010 Oct;24(10):3882-94
pubmed: 20522783
Mech Ageing Dev. 2000 Dec 1;120(1-3):111-25
pubmed: 11087909
Cytotechnology. 2018 Feb;70(1):387-396
pubmed: 29230631
BMB Rep. 2017 Mar;50(3):144-149
pubmed: 28193314
Mol Cell Biol. 2010 Aug;30(15):3827-41
pubmed: 20516217

Auteurs

Albena Momchilova (A)

Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev Str. bl.21, 1113 Sofia, Bulgaria.

Roumen Pankov (R)

Biological Faculty, Sofia University "St. Kliment Ohridki", 8, Dragan Tzankov Str., 1164 Sofia, Bulgaria.

Galya Staneva (G)

Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev Str. bl.21, 1113 Sofia, Bulgaria.

Stefan Pankov (S)

Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev Str. bl.21, 1113 Sofia, Bulgaria.

Plamen Krastev (P)

Cardiology Clinic, University Hospital "St. Ekaterina", 1431 Sofia, Bulgaria.

Evgenia Vassileva (E)

Clinic of Neurology, Tsaritsa Yoanna University Hospital-ISUL, 1527 Sofia, Bulgaria.

Rusina Hazarosova (R)

Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev Str. bl.21, 1113 Sofia, Bulgaria.

Nikolai Krastev (N)

Department of Anatomy, Histology and Embryology, Medical University-Sofia, Blvd. Sv. Georgi Sofiisky 1, 1431 Sofia, Bulgaria.
Medical Center Relax, 8 Ami Bue Str., 1606 Sofia, Bulgaria.

Bozhil Robev (B)

Department of Medical Oncology, University Multi-Profile Hospital for Active Treatment (UMHAT) "St. Ivan Rilski", 1606 Sofia, Bulgaria.

Biliana Nikolova (B)

Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev Str. bl.21, 1113 Sofia, Bulgaria.

Adriana Pinkas (A)

CSTEP, Office of Continuing Education, Suffolk County Community College 30 Greene Ave., Sayville, NY 11782, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH